Aggrecan Antibody, N-terminal Neoepitope FFGV

Product Description

Aggrecan Antibody, N-terminal Neoepitope FFGV
Catalog number: B2026954
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 ug
Molecular Weight or Concentration: 0.1 mg/mL
Supplied as: Solution
Storage: −20°C
Keywords: ACAN, Cartilage-specific proteoglycan core protein, CSPCP, Chondroitin sulfate proteoglycan core protein 1, Chondroitin sulfate proteoglycan 1, Aggrecan core protein 2, Aggrecan proteoglycan, CSPGCP

References:
1. Hughes CE, Little CB, Buttner FH, Bartnik E, Caterson B. An antigen substitution ELISA for the quantification of aggrecan-degradation products that possess the MMP-generated neoepitope …FFGVG. Glycobiology. 1995;5:773-81.
2. Little CB, Flannery CR, Hughes CE, Mort JS, Roughley PJ, Alberte C, Caterson B. Aggrecanase versus matrix metalloproteinases in a rat model of cartilage degradation. Arthritis Rheum. 1999;42:1489-99.
3. Caterson B, Flannery CR, Hughes CE, Little CB. Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol. 2000;19:333-44.
4. Little CB, Hughes CE, Curtis CL, Janusz MJ, Bohne R, Wang-Weigand S, Caterson B. Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation. Matrix Biol. 2002;21:271-88.
5. Lark MW, Gordy JT, Weidner JR, Ayala J, Christie CI, Williams EN, Mumford RA, Lohmander LS, Hoerrner LA, Rhodes RK. Cell-mediated catabolism of aggrecan. Evidence that cleavage at the G1-G2 interglobular domain, GD1-G2, is mediated by a matrix metalloproteinase in rat and human cartilage. Biochem J. 1995;307:245-52.
6. Fosang AJ, Last K, Gardiner P, Jackson DC, Brown L. Development of a specific enzyme-linked immunosorbent assay for measuring soluble aggrecan fragments containing the DIPEN neoepitope. Biochem J. 1995;305:347-51.
7. Roberts S, Caterson B, Evans H, Darby S, Eisenstein SM. Characterization of the aggrecan in the human intervertebral disc using ‘neoepitope’ antibodies. Spine. 2000;25:1146-51.
8. Sandy JD, Neame PJ, Boynton RE, Flannery CR. Catabolism of aggrecan in cartilage explants. Identification of a major cleavage site within the interglobular domain. J Biol Chem. 1991;266:8683-5.
9. Struglics A, Larsson S, Pratta MA, Kumar S, Lark MW, Lohmander LS. Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage. 2006;14:101-13.
10. Malfait AM, Ritchie J, Gil AS, Austin JS, Hartke J, Qin W, Tortorella MD, Arner EC. Adamts5 deficient mice are protected from osteoarthritis. Nature. 2005;434:648-51.
Aggrecan Antibody, N-terminal neoepitope FFGV

Products Related to Aggrecan Antibody, N-terminal Neoepitope FFGV can be found at Antibodies